Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. (2018)

First Author: Russell RJ
Attributed to:  Wessex severe asthma cohort funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S2213-2600(18)30201-7

PubMed Identifier: 29793857

Publication URI: http://europepmc.org/abstract/MED/29793857

Type: Journal Article/Review

Volume: 6

Parent Publication: The Lancet. Respiratory medicine

Issue: 7

ISSN: 2213-2600